Sanofi: We're looking for biotech deals
Following yesterday's investment in Regeneron, Sanofi-Aventis' Marc Cluzel (photo) reiterated the company's plans to aggressively pursue biotech buyouts. "If there is a good deal to be done, we will do it. We are very pragmatic," Cluzel told investors. Currently, only 10 percent of the drugs Sanofi makes are biologics; the company wants to boost that number to 20 or 30 percent by 2012.
Sanofi isn't the only big pharma that has shifted its focus to biotech. Pfizer has been on a year-long crusade to expand its biotech efforts, and AstraZeneca formed a massive biotech unit when it united Cambridge Antibody Technologies with MedImmune to form a biotech powerhouse. As more big developers fill their pipelines with biologics, competition for the most promising biotech drugs is going to get tough.
- see this report for more
Related Articles:
Lines blur as Big Pharma crosses borders into biotech. Report
Sanofi snags bigger stake, new pact with Regeneron. Report
Sanofi underscores pipeline advances, setbacks. Report
Comments (1) | Post a comment
More stories about Biologics buyouts Regeneron investment pharmaceuticals AstraZeneca Pfizer Sanofi Aventis biotech drugs MedImmune
Comments
By Raif Tawakol | Posted 5:20pm | November 30, 2007
Sanofi, BMS and A-Z are looking out there scrambling far in the distant future of the development technology. While there are products that far far more worthy of development sooner rather than in the distant future.
A few products that are potential blockbuster in magnitude for the cardiovascular lipid lowering arena, that are viewed as not so "sexy" just because because the true clinical know how is limited.
These companies are totally driven by hot new technology, then they go out to explain how useful after deveopment of the product.
While if they stopped to look at clinical solutions that are available and practically ready to go, they would reap benefits in the multiples of billions of dollars.
Every one of those companies has a physician "Guru" on staff that is not a clinician. They get advice from so called other physician Professor that is really not a true deep down clinician, but a teacher a reader of clinical science like the pilot trainer who spends his entire career teaching on airline simulators.
Those physicians cannot catch the escence of clinical pharmaceutical discovery.
Cardient has a pipeline that would remedy some of those woes easily woth 4-6 billion.
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
